VIPASY-Palbociclib Co-Treatment Modulates the Expression of Markers Involved in HCT-116 Cell Regulation

Vol 3, 2024. - 320602
Poster
Favorite this paper
How to cite this paper?
Abstract

Colon cancer is a major contributor to cancer mortality globally, with few treatment alternatives for advanced cases. Targeting both cell proliferation and apoptosis pathways has become a promising approach in anticancer therapy. Palbociclib, a CDK4/6 inhibitor, has shown efficacy in halting cancer cell proliferation by disrupting cell cycle progression. Meanwhile, the VIPASY peptide from cowpea bean’s β-vignin protein has shown the potential to induce cell death in HCT-116 colon cancer cells by modulating the apoptotic pathway. Therefore, in this study, we investigated the effects of VIPASY, palbociclib, and their combination on HCT-116 colon cancer cells, focusing on key molecular markers associated with cell survival, cell cycle regulation, and apoptosis. Cell viability of colon cancer cells (HCT-116) was assessed after 24h treatment with VIPASY peptide (200 µM), palbociclib (PAL) (280 µM), and their combination/co-treatment (VIPASY 200 µM + PAL 280 µM). The relative protein expression of apoptotic markers (TNF-R1, caspase-4, caspase-8) and survival/cell cycle-related markers (SIRT1, thioredoxin, Cdc2) on HCT-116 cells treated for 24 h with VIPASY peptide, palbociclib (PAL) and their co-treatment (VIPASY + PAL) was evaluated. HCT-116 cell viability was affected by VIPASY (64%) and palbociclib (72%), however, co-treatment of VIPASY+PAL had a more significant effect on reducing the viability (45%). TNF-R1 was significantly downregulated with VIPASY-PAL treatment (-70%) compared to VIPASY treatment (-18%), and caspase-8 was upregulated with VIPASY-PAL treatment (+35%), suggesting that the VIPASY-PAL treatment might induce apoptosis by the extrinsic pathway. Thioredoxin, a key antioxidant protein that is often overexpressed in cancer cells, was downregulated with VIPASY (-38%), palbociclib (-23%), and even more with VIPASY-PAL treatment (-57%). Caspase-4 and SIRT1 were not affected by VIPASY-PAL treatment (p>0.05). And Cdc2 expression, a key player in cell cycle regulation, was reduced by 90% following VIPASY-PAL treatment. Our work shows the potential of VIPASY-palbociclib co-treatment on HCT-116 cells.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 UFBA
  • 2 UIUC
  • 3 UFAM
Track
  • Nutrition, functional foods and bioactive compounds, fortified foods, food microbiology – (AS)
Keywords
Anticancer peptides
Colon cancer
Caspase-8
Cdc2